<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81604</article-id><article-id pub-id-type="doi">10.7554/eLife.81604</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-304177"><name><surname>Jean-Pierre</surname><given-names>Fabrice</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287571"><name><surname>Hampton</surname><given-names>Thomas H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250862"><name><surname>Schultz</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-117099"><name><surname>Hogan</surname><given-names>Deborah A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287572"><name><surname>Groleau</surname><given-names>Marie-Christine</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287573"><name><surname>Déziel</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-249762"><name><surname>O'Toole</surname><given-names>George A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2861-4392</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Microbiology and Immunology</institution>, <institution>Dartmouth College</institution>, <addr-line><named-content content-type="city">Hanover</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Centre Armand-Frappier Santé Biotechnologie</institution>, <institution>Institut National de la Recherche Scientifique</institution>, <addr-line><named-content content-type="city">Laval</named-content></addr-line>, <country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-79713"><name><surname>Cooper</surname><given-names>Vaughn S</given-names></name><role>Reviewing editor</role><aff><institution>University of Pittsburgh</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>fabricejean-pierre@dartmouth.edu</email> (FJ);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>georgeo@dartmouth.edu</email> (GO);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>01</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e81604</elocation-id><history><date date-type="received"><day>04</day><month>07</month><year>2022</year></date><date date-type="accepted"><day>19</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Jean-Pierre et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Jean-Pierre et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81604-v1.pdf"/><abstract><p>Interspecies interactions can drive the emergence of unexpected microbial phenotypes that are not observed when studying monocultures. The cystic fibrosis (CF) lung consists of a complex environment where microbes, living as polymicrobial biofilm-like communities, are associated with negative clinical outcomes for persons with CF (pwCF). However, the current lack of <italic>in vitro</italic> models integrating the microbial diversity observed in the CF airway hampers our understanding of why polymicrobial communities are recalcitrant to therapy in this disease. Here, integrating computational approaches informed by clinical data, we built a mixed community of clinical relevance to the CF lung composed of <italic>Pseudomonas aeruginosa</italic>, <italic>Staphylococcus aureus</italic>, <italic>Streptococcus sanguinis</italic> and <italic>Prevotella melaninogenica</italic>. We developed and validated this model biofilm community with multiple isolates of these four genera. When challenged with tobramycin, a front-line antimicrobial used to treat pwCF, the microorganisms in the polymicrobial community show altered sensitivity to this antibiotic compared to monospecies biofilms. We observed that wild-type <italic>P. aeruginosa</italic> is sensitized to tobramycin in a mixed community versus monoculture, and this observation holds across a range of community relative abundances. We also report that LasR loss-of-function, a variant frequently detected in the CF airway, drives tolerance of <italic>P. aeruginosa</italic> to tobramycin specifically in the mixed community. Our data suggest that the molecular basis of this community-specific recalcitrance to tobramycin for the <italic>P. aeruginosa</italic> LasR mutant is increased production of phenazines. Our work support the importance of studying a clinically-relevant model polymicrobial biofilms to understand community-specific traits relevant to infections.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000897</institution-id><institution>Cystic Fibrosis Foundation</institution></institution-wrap></funding-source><award-id>JEAN21F0</award-id><principal-award-recipient><name><surname>Jean-Pierre</surname><given-names>Fabrice</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AI155424</award-id><principal-award-recipient><name><surname>O'Toole</surname><given-names>George A</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>MOP-142466</award-id><principal-award-recipient><name><surname>Déziel</surname><given-names>Eric</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>5 P20 GM130454</award-id><principal-award-recipient><name><surname>Schultz</surname><given-names>Daniel</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000897</institution-id><institution>Cystic Fibrosis Foundation</institution></institution-wrap></funding-source><award-id>HOGAN19G0</award-id><principal-award-recipient><name><surname>Hogan</surname><given-names>Deborah A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Figure 1 - figure supplement 3 &amp; Source Data 1 contains the numerical data used to generate the figure.Figure 1 - figure supplement 4 &amp; Source Data 2 contains numerical data used to generate the figure.Source Code 1 contains the script used to generate Figure 1, Figure 1 - figure supplement 1 and Figure 1 - figure supplement 4.Source Code 2 contains the script used to generate the modeling data presented Figure 1 - figure supplement 1.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Hampton TH</collab><collab>Thomas D</collab><collab>van der Gast C</collab><collab>O'Toole GA</collab><collab>Stanton BA</collab></person-group><year iso-8601-date="2021">2021</year><source>Mild Cystic Fibrosis Lung Disease Is Associated with Bacterial Community Stability</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJEB30646">https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJEB30646</ext-link><comment>NCBI BioProject, PRJEB30646</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-81604-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>